Merus (NASDAQ:MRUS – Get Free Report) COO Peter B. Silverman sold 10,000 shares of the stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Merus Price Performance
NASDAQ MRUS opened at $59.17 on Friday. The company’s 50-day simple moving average is $50.49 and its two-hundred day simple moving average is $42.77. Merus has a one year low of $19.81 and a one year high of $61.61.
Merus (NASDAQ:MRUS – Get Free Report) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24. The business had revenue of $7.89 million for the quarter, compared to the consensus estimate of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. Analysts predict that Merus will post -3.1 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities research analysts have recently weighed in on MRUS shares. Truist Financial increased their target price on shares of Merus from $69.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th. Guggenheim increased their target price on shares of Merus from $57.00 to $93.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. StockNews.com downgraded shares of Merus from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Bank of America reaffirmed a “buy” rating and issued a $76.00 price target on shares of Merus in a research note on Tuesday. Finally, Canaccord Genuity Group raised their price target on shares of Merus from $54.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $80.90.
Get Our Latest Stock Report on Merus
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
See Also
- Five stocks we like better than Merus
- How to Read Stock Charts for Beginners
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- How to Invest in Blue Chip Stocks
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Election Stocks: How Elections Affect the Stock Market
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.